Leqvio vs Losartan: What You Need to Know Before Switching

Why This Comparison Is Clinically Unusual

Leqvio and losartan address two different cardiovascular risk factors: elevated LDL cholesterol and elevated blood pressure. Comparing them directly is a bit like comparing a statin to a diuretic. Each occupies a separate lane in the cardiometabolic treatment algorithm, which means "switching between them" almost always requires a more specific clinical question before a physician can give meaningful guidance.

They target different physiological pathways

Inclisiran works by delivering a double-stranded siRNA molecule into hepatocytes, where it degrades messenger RNA encoding PCSK9. Less PCSK9 means more LDL receptors remain on the hepatocyte surface to clear circulating LDL particles. In the pooled ORION-10 and ORION-11 trials (N=3,457 combined), inclisiran 300 mg produced a time-averaged LDL-C reduction of approximately 50% from baseline compared with placebo, sustained over 18 months of follow-up [1].

Losartan competitively blocks the angiotensin II type 1 (AT1) receptor, reducing vasoconstriction and aldosterone secretion. Its primary clinical indication is hypertension, though it carries additional indications for diabetic nephropathy and heart failure. In the LIFE trial (N=9,193), losartan-based therapy reduced the composite primary endpoint of cardiovascular death, stroke, and myocardial infarction by 13% compared with atenolol (relative risk 0.87, P=0.021) [2].

They are often used simultaneously

Because hypercholesterolemia and hypertension commonly coexist, a patient taking losartan for blood pressure control and inclisiran for LDL reduction is not an unusual clinical picture. The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease explicitly supports addressing multiple risk factors concurrently rather than sequentially [3]. Stopping one drug to start the other would leave one risk factor unmanaged, which carries real long-term hazard.

Mechanism and Pharmacology: Inclisiran vs Losartan

How inclisiran (Leqvio) works

Inclisiran is the first siRNA-based lipid-lowering drug approved by the FDA (December 2021) [4]. After subcutaneous injection, it is taken up by hepatocytes via the GalNAc (N-acetylgalactosamine) conjugate. Inside the cell, it joins the RNA-induced silencing complex (RISC) and catalytically cleaves PCSK9 mRNA. The silencing is not permanent, but it is durable: a single injection suppresses PCSK9 protein for roughly six months, which is why the approved dosing schedule requires only two injections per year after the initial loading phase [4].

The durability is clinically significant. Adherence to daily oral lipid therapy is a persistent real-world problem, with some registry analyses suggesting fewer than 50% of statin users remain on therapy at 12 months. A twice-yearly injection administered in a clinical setting largely sidesteps this issue.

How losartan works

Losartan was the first orally active AT1 antagonist approved in the United States (1995) [5]. It is a prodrug: hepatic conversion produces the active metabolite EXP-3174, which has 10 to 40 times greater AT1-receptor affinity and a half-life of 6 to 9 hours. This results in 24-hour blood pressure coverage from once-daily dosing. Losartan's nephroprotective mechanism involves both hemodynamic (reduced glomerular filtration pressure) and non-hemodynamic pathways, including attenuation of TGF-beta-mediated renal fibrosis [5].

Unlike ACE inhibitors, losartan does not increase bradykinin levels and therefore carries a substantially lower risk of cough, a practical advantage that improves long-term tolerability.

Side-effect profiles differ substantially

Inclisiran's most frequent adverse event is injection-site reactions, occurring in roughly 8.2% of participants in the ORION trials compared with 1.8% for placebo [1]. No clinically significant hepatotoxicity, myopathy, or new-onset diabetes signal has emerged in phase 3 data.

Losartan's main safety concerns include hyperkalemia (particularly in patients with chronic kidney disease or concurrent potassium-sparing diuretics), hypotension with the first dose, and rare angioedema. It carries a black-box warning for fetal toxicity and must be stopped in pregnancy [5].

Efficacy: What the Evidence Actually Shows

LDL reduction with inclisiran

The ORION-10 trial (N=1,561, patients with atherosclerotic cardiovascular disease on statin background) demonstrated an LDL-C reduction of 52.3% from baseline at Day 510 in the inclisiran group versus a 0.5% increase in the placebo group (P<0.001) [1]. ORION-11 (N=1,617, broader ASCVD or ASCVD-risk-equivalent population) showed a 49.9% reduction at Day 510 versus a 0.8% reduction with placebo (P<0.001) [1].

These are reductions on top of existing statin therapy in most participants. Inclisiran is not a statin alternative; it is an add-on agent for patients who cannot reach LDL targets on statins alone, or who are statin-intolerant.

Blood pressure reduction with losartan

In the LIFE trial, the losartan-based regimen produced mean systolic blood pressure reductions of approximately 30 mmHg over a mean follow-up of 4.8 years [2]. Critically, the 13% relative risk reduction in the composite primary endpoint was observed against an active comparator (atenolol), not placebo, suggesting a class-specific benefit for ARBs in hypertensive patients with left ventricular hypertrophy beyond blood pressure lowering alone [2].

The guideline quotation that contextualizes this: the 2017 ACC/AHA Hypertension Guideline states, "For patients who have an indication for a specific drug class (e.g., ARBs for diabetic nephropathy), that drug class should be used as part of the blood pressure lowering regimen." [6]

No head-to-head cardiovascular outcomes trial exists

No randomized controlled trial has directly compared inclisiran and losartan on major adverse cardiovascular events (MACE). They treat different risk factors, so such a trial would not be scientifically meaningful. What does exist is evidence that LDL lowering and blood pressure lowering provide largely independent and additive cardiovascular risk reduction.

The HealthRX Clinical Decision Framework below summarizes how to think about these two drugs in the same patient:

HealthRX Dual-Risk-Factor Framework for Inclisiran + Losartan Decision-Making

| Clinical Scenario | Recommended Approach | |---|---| | High LDL only (BP controlled) | Add inclisiran if LDL remains above target on maximally tolerated statin | | High BP only (LDL controlled) | Losartan per JNC/ACC-AHA hypertension algorithm | | Both high LDL and high BP | Both drugs may be indicated; consult prescribing clinician | | Statin-intolerant, high LDL | Inclisiran is an appropriate option; losartan does not lower LDL | | CKD with proteinuria and high BP | Losartan preferred; inclisiran added if LDL still elevated | | Pregnancy (any stage) | Losartan contraindicated; inclisiran lacks adequate safety data |

Switching Between Leqvio and Losartan: A Clinical Breakdown

When "switching" is actually a discontinuation decision

A patient asking about switching from inclisiran to losartan (or vice versa) is usually experiencing one of three clinical situations:

1. A new diagnosis of hypertension in a patient already on inclisiran.
2. An LDL target miss in a patient already on losartan.
3. A drug intolerance that prompts re-evaluation of the entire regimen.

In the first two scenarios, "switching" is the wrong framing. Adding is the correct clinical action because the two drugs address separate risk factors [3]. In the third scenario, the clinician needs to identify which drug is causing the problem before any substitution is made.

What stopping inclisiran actually means

Inclisiran's duration of action creates an important discontinuation consideration. After the last injection, PCSK9 mRNA silencing wanes over roughly six months. LDL levels begin to rise back toward baseline. A patient who stops inclisiran without an alternative lipid-lowering plan in place may see LDL levels return to pre-treatment values by 9 to 12 months post-dose [1]. For a high-risk ASCVD patient, that trajectory increases event risk. Restarting or transitioning to another LDL-lowering agent (another PCSK9 inhibitor, ezetimibe, or resumption of statin therapy) should be part of the discontinuation plan.

What stopping losartan actually means

Abrupt discontinuation of losartan in a patient with hypertension may cause a rebound rise in blood pressure. In patients with diabetic nephropathy, stopping losartan removes its kidney-protective effect, which operates partly independently of blood pressure reduction. The 2012 KDIGO clinical practice guidelines on blood pressure in CKD specifically recommend ARB or ACE inhibitor use for patients with diabetes, hypertension, and urine albumin-creatinine ratio above 30 mg/g [7].

Transitioning between PCSK9 inhibitors vs switching from inclisiran to an ARB

If the goal is to maintain LDL lowering via a different mechanism, switching from inclisiran to evolocumab (Repatha) or alirocumab (Praluent) is medically coherent. Both are monoclonal antibodies targeting PCSK9 protein directly, requiring subcutaneous injection every 2 or 4 weeks. Neither has been tested head-to-head against inclisiran in a dedicated comparative trial, but the FOURIER trial (evolocumab, N=27,564) demonstrated a 15% reduction in the composite of cardiovascular death, MI, stroke, coronary revascularization, or unstable angina over a median 2.2 years [8].

Switching from inclisiran to losartan does not maintain LDL control. They are not interchangeable.

Cost, Access, and Adherence Considerations

Cost and insurance coverage

Losartan is generic and widely available, with a 30-day supply often costing under $15 at major pharmacy chains. Inclisiran carries a list price of approximately $3,250 per injection in the United States as of early 2025, though manufacturer patient-assistance programs and specialty pharmacy contracts may reduce out-of-pocket costs substantially. Insurance coverage for inclisiran typically requires documentation of statin intolerance or failure to reach LDL goals on maximally tolerated therapy.

Adherence patterns

Daily oral medications have known adherence challenges. A 2019 analysis in the Journal of the American College of Cardiology found that only 56% of patients prescribed high-intensity statin therapy remained adherent at 12 months in real-world settings [9]. Losartan, as a once-daily oral drug, faces similar adherence headwinds. Inclisiran's office-administered injection removes patient adherence from the equation entirely after the prescribing decision is made, which may confer a real-world effectiveness advantage not fully captured in clinical trials.

Patient preference and route of administration

Some patients have needle aversion that makes twice-yearly injections feel burdensome despite the infrequency. Others prefer an injection over the daily routine of oral therapy. Shared decision-making should account for these preferences, particularly when both a PCSK9 inhibitor and an ARB are under consideration as part of the same regimen.

Who Should Consider Each Drug (or Both)

Inclisiran is appropriate when:

• LDL-C remains above guideline-recommended targets on maximally tolerated statin therapy (target: <70 mg/dL in very high-risk ASCVD, per ACC/AHA 2018 Cholesterol Guidelines) [10].
• A patient has confirmed statin intolerance and ezetimibe monotherapy is insufficient.
• Adherence to daily oral lipid-lowering therapy is poor and a supervised injectable regimen is clinically preferable.

Losartan is appropriate when:

• A patient has hypertension with systolic BP persistently above 130 mmHg (Stage 1 by 2017 ACC/AHA criteria) [6].
• Type 2 diabetes is present with diabetic nephropathy or proteinuria.
• Heart failure with reduced ejection fraction is being managed and the patient cannot tolerate ACE inhibitors.
• Stroke prevention in hypertensive patients with left ventricular hypertrophy, as supported by LIFE [2].

Both drugs together:

A patient with established ASCVD, LDL of 95 mg/dL on rosuvastatin 20 mg, and blood pressure of 148/92 mmHg might reasonably be on both inclisiran and losartan simultaneously. Neither drug interacts with the other in a clinically meaningful way. Renal function and potassium should be monitored when any ARB is added to a regimen, but inclisiran does not affect electrolyte handling.

Dr. Kausik Ray, one of the principal investigators of the ORION trials, has stated: "Inclisiran offers a fundamentally different model for long-term LDL management, one that shifts the compliance burden from the patient to the healthcare system." This perspective is consistent with the drug's approval rationale for patients who require sustained LDL lowering beyond what daily oral therapy reliably delivers in practice.

Safety Monitoring When Using These Drugs

Monitoring for inclisiran

The FDA label for inclisiran does not require routine liver function monitoring, though baseline hepatic assessment is standard practice [4]. Kidney function is not a dose-adjustment parameter for inclisiran given its hepatocyte-targeting delivery mechanism. Injection site reactions are the primary ongoing monitoring consideration.

Monitoring for losartan

Serum potassium and creatinine should be checked 1 to 2 weeks after initiating losartan or any dose increase, then periodically at 3 to 6 months, per standard nephrology and primary care protocols [7]. Hyperkalemia (potassium >5.5 mEq/L) may warrant dose reduction or discontinuation. Blood pressure response should be assessed at 4 weeks after initiation.

Drug interactions

Losartan interacts with NSAIDs (reduced antihypertensive effect and increased renal risk), potassium supplements, aldosterone antagonists, and lithium. Inclisiran has no significant cytochrome P450-based drug interactions identified in phase 3 data, though its prescribing information advises caution in patients with severe hepatic impairment [4].